Drag a card by its title · ⚙ to size, swap or remove

The company

Seaport Therapeutics, Inc.

SPTX · Nasdaq

Health CareBiotechnology

We hold no 150-day reading for SPTX yet: it needs about 200 sessions of history. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: not in the set
Weeks in an uptrend: —
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $40.1M
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 53

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3

Sale orders, 12 months0

Buyers · sellers3 · 0

Who	Did	Shares	Traded
Robert J. HombachDirector	bought	13,000at $18.14	22 Jun 2026filed 24 Jun 2026
Arch Venture Partners Xii, Llc10% owner	bought	1,100,000at $18.00	4 May 2026filed 4 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders53

New · exited53 · 0

Reported value$786.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
ARCH Venture Management, LLCnew · filed 14 Aug 2026	6,294,951$136.6M	+6,294,951
GENERAL ATLANTIC, L.P.new · filed 14 Aug 2026	6,101,582$132.5M	+6,101,582
Sofinnova Investments, Inc.new · filed 14 Aug 2026	3,564,871$77.4M	+3,564,871
GOLDMAN SACHS GROUP INCnew · filed 14 Aug 2026	2,178,642$47.3M	+2,178,642
TRV GP VI, LLCnew · filed 10 Aug 2026	2,061,222$44.8M	+2,061,222
CANADA PENSION PLAN INVESTMENT BOARDnew · filed 14 Aug 2026	1,975,791$42.9M	+1,975,791
JPMORGAN CHASE & COnew · filed 12 Aug 2026	1,815,845$40.9M	+1,815,845
Foresite Capital Management VI LLCnew · filed 14 Aug 2026	1,779,521$38.7M	+1,779,521
FMR LLCnew · filed 13 Aug 2026	1,185,100$25.7M	+1,185,100
Bellevue Group AGnew · filed 14 Aug 2026	1,100,000$23.9M	+1,100,000

News

Seaport Therapeutics, Inc.: Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congressfinanznachrichten.de · 9 Oct 2026

Everyone who traded it

Robert J. Hombach Director · last 22 Jun 20261 · 0

Antony Loebel Chief Medical Officer · last 4 May 20260 · 0

Arch Venture Partners Xii, L.p. 10% owner · last 4 May 20261 · 0

ARCH Venture Partners XII, LLC 10% owner · last 4 May 20261 · 0

Denice Torres Director · last 4 May 20260 · 0

James Healy Director · last 4 May 20260 · 0

Lana Gladstein General Counsel · last 4 May 20260 · 0

Lauren White Chief Financial Officer · last 4 May 20260 · 0

Michael Cunyuan Chen Chief Scientific Officer · last 4 May 20260 · 0

PureTech Health plc 10% owner · last 4 May 20260 · 0

Steven M. Paul Director · last 4 May 20260 · 0

Daphne Zohar Chief Executive Officer · last 30 Apr 20260 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

No ratio computed from its SEC filings yet.

Analyst forecasts

No analyst forecasts yet.